Cirrus Pharmaceuticals announced that it has hired Andrew Hamer as VP R&D. Hamer was most recently Senior Director of R&D Operations at GSK’s dermatology subsidiary Stiefel. He also has experience in OINDP development at Cardinal, Sanofi, and Covance.
Cirrus, based in Research Triangle Park, NC, was acquired by Kemwell in 2013. It offers inhalation and nasal development services as well as analytical testing. In October 2014, Cirrus announced that it was building a cGMP facility that would add manufacturing capabilities.
Hamer commented, “I’m thrilled to have joined Cirrus and feel very privileged to be here. I’m looking forward to working with so many talented people and building on the Cirrus/Kemwell heritage here in RTP to create a world class development organization that will be a partner of choice.”
Kemwell VP Corporate Development Karan Bagaria said, “We are excited to have Andrew join Cirrus, a Kemwell Company. Andrew brings a wealth of experience and knowledge in development of products for different dosage forms and will help support our customers’ programs and enhance the value we bring to them.”
Read the Cirrus Pharmaceuticals press release.
